RA
HSTO

Royce & Associates’s Histogen Inc. Common Stock HSTO Stock Holding History

Royce & Associates’s Portfolio HSTO Stock Details HSTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-5
Closed -$4K – 1297
2017
Q4 		$4K Buy
5
+2
+67% +$1.85K ﹤0.01% 1241
2017
Q3 		$3K Buy
+3
New +$3.41K ﹤0.01% 1232

Other funds holding HSTO

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return

Royce & Associates's HSTO Position: Q1 2018 in Review

Royce & Associates sold out of Histogen Inc. Common Stock (HSTO) in Q1 2018, closing a stake of 5 shares — an estimated $4K sold.

Royce & Associates first reported a position in HSTO in Q3 2017 and held it in 2 quarters. The position peaked at $4K in Q4 2017. 73 funds tracked by Wall St. Rank hold HSTO as of Q1 2018.

  • Royce & Associates reported no remaining Histogen Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Royce & Associates sold 5 Histogen Inc. Common Stock shares in Q1 2018, an estimated $4K.
  • Royce & Associates first reported a position in Histogen Inc. Common Stock in Q3 2017 and held it in 2 quarters.
  • Royce & Associates's Histogen Inc. Common Stock position peaked at $4K in Q4 2017.
  • 73 funds tracked by Wall St. Rank held Histogen Inc. Common Stock as of Q1 2018.

Based on Royce & Associates's 13F filing for Q1 2018, filed 14 May 2018.